MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
5.87
-0.01
-0.17%
Closed 16:10 12/12 EST
OPEN
5.88
PREV CLOSE
5.87
HIGH
6.04
LOW
5.79
VOLUME
648.28K
TURNOVER
--
52 WEEK HIGH
7.37
52 WEEK LOW
2.410
MARKET CAP
457.33M
P/E (TTM)
-2.3542
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLDB last week (1208-1212)?
Weekly Report · 2h ago
SOLID BIOSCIENCES TO SHOWCASE PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101 AND CARDIAC GENE THERAPY PIPELINE AT THE 22ND GLOBAL CARDIOVASCULAR CLINICAL TRIALISTS (CVCT) FORUM
Reuters · 6d ago
Weekly Report: what happened at SLDB last week (1201-1205)?
Weekly Report · 12/08 09:08
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst
Benzinga · 12/04 20:38
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 12/04 14:21
Solid Biosciences Price Target Announced at $16.00/Share by Needham
Dow Jones · 12/04 12:12
Needham Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $16
Benzinga · 12/04 12:02
Needham starts Solid Biosciences at Buy on opening in DMD market
TipRanks · 12/04 11:50
More
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.